Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma

Opinion
Video

Compare outcomes between ide-cel chimeric antigen receptor T-cell (CAR-T) therapy and standard treatment regimens such as pomalidomide and daratumumab combinations in patients with heavily pretreated relapsed and refractory multiple myeloma.

Recent Videos
“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.
Barry Paul, MD, listed cilta-cel, anito-cel, and arlo-cel as 3 of the CAR T-cell therapies with the most promising efficacy in patients with multiple myeloma.
Elucidating nonresponses to bispecific T-cell engagers may be an important research consideration in the multiple myeloma field.
Fixed treatment durations with bispecific antibodies followed by observation may help in mitigating infection-related AEs, according to Shebli Atrash, MD.
Shebli Atrash, MD, stated that MRD should be considered carefully as an end point, given potential recurrence despite MRD negativity.
The National ICE-T Conference may inspire future collaboration between community and academic oncologists in the management of different cancers.
Long-term toxicities like infections and secondary primary malignancies remain a concern when sequencing novel agents for those with multiple myeloma.
Related Content
We found that patients who are [complete remission] MRD-negative, and PET/CT negative year after year for 5 years do not have to be maintained.

Evaluating the Proximity and Impact of a Cure in Multiple Myeloma

Tim Cortese
September 10th 2025
Article

According to Sundar Jagannath, MBBS, the cure for multiple myeloma was observed in patients who were cancer free for 5 years without maintenance therapy.

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Navigating AE Management for Cellular Therapy Across Hematologic Cancers

Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 11th 2025
Podcast

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

In unweighted analyses, significant PFS improvements were observed, highlighting the differences in restricted mean survival time of 6.95 months.

Elranatamab and MagnetisMM-3 Results Are Superior to Real-World Multiple Myeloma Outcomes

Tim Cortese
August 24th 2025
Article

An observational study reported that results with elranatamab for patients with RRMM from the MagnetisMM-3 trial were superior to what was observed across 5 centers in the UK.

Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

Mitigating AEs and Protecting QOL Following Talquetamab in Multiple Myeloma

Samantha Shenoy, NP, MSN
October 14th 2024
Podcast

Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

Bridging therapy with talquetamab achieved “notable” disease control among patients with multiple myeloma in a retrospective study.

Talquetamab Bridging Strategy Appears Feasible in R/R Multiple Myeloma

Russ Conroy
August 20th 2025
Article

Bridging therapy with talquetamab achieved “notable” disease control among patients with multiple myeloma in a retrospective study.

Therapy with anti-CD38 monoclonal antibodies significantly increased the minimal residual disease–negative rate.

Further Research on Anti-CD38 mAbs Warranted in Multiple Myeloma

Tim Cortese
August 19th 2025
Article

A systematic review of 8 randomized trials showed that anti-CD38 monoclonal antibodies did not improve overall survival in high-risk subgroups.